Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants

The company last month refiled — for a third time — a new drug application seeking approval for its experimental skin disorder therapy.

Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants
The company last month refiled — for a third time — a new drug application seeking approval for its experimental skin disorder therapy.